Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) | |
US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
6
United States
4
Korea, Republic of
2
China
2
European Union
1
South Africa
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Uruguay
1
Argentina
1
Colombia
1
Brazil
1
Spain
1
Chile
1
Taiwan, Province of China
1
Ukraine
1
Japan
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(7 years from now) | |
US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(7 years from now) |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
5
United States
4
European Union
3
Denmark
3
Slovenia
3
Portugal
3
Spain
3
Poland
3
Japan
2
Hong Kong
2
Hungary
2
Argentina
2
Croatia
2
China
1
South Africa
1
Mexico
1
Australia
1
Russia
1
Lithuania
1
Uruguay
1
Brazil
1
Cyprus
1
Korea, Republic of
1
San Marino
1
Chile
1
Taiwan, Province of China
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic